Opinion

Video

KEYNOTE-361 Highlights: Challenges and Insights

Thomas Powles, MBBS, MRCP, MD, discusses how the KEYNOTE-361 trial failed because of the trial’s design. Data show that the maintenance phase of the trial is what was driving the benefit and that the longest survival with this trial was 17 months with both pembrolizumab and chemotherapy treatment rather than just chemotherapy.

Related Videos
2 experts are featured in this series.
2 expert is featured in this series.